Banner

Article

Linagliptin cardiovascular safety profile appears superior to glimepiride

Cardiovascular events were fewer in patients with type 2 diabetes randomized to 2 years of the DPP-4 inhibitor linagliptin compared with glimepiride as add-on therapy to metformin, according to data from a phase III study.

Related Videos
Related Content
© batuhan toker - stock.adobe.com
May 9th 2025

The rise of early-onset cancers; new NASEM report urges action on Lyme infection-associated chronic illness; even short-term sleep loss raises risk of heart disease – Morning Medical Update

Off the Chart: A Business of Medicine Podcast - Physician panel: Navigating the 2025 vaccination crisis
May 7th 2025

Physician panel: Navigating the 2025 vaccination crisis

Casey Means, MD © caseymeans.com
May 8th 2025

Who is Casey Means, MD? Trump’s new surgeon general pick

Off the Chart: A Business of Medicine Podcast - Ep. 63: Healthy eating with Chef Dr. Mike
May 5th 2025

Ep. 63: Healthy eating with Chef Dr. Mike

Early career physicians need to make smart money moves: ©New Africa - stock.adobe.com
May 8th 2025

Securing your future: Essential financial considerations for early career physicians

© Andrii Yalanskyi - stock.adobe.com
May 8th 2025

LeagueMed offers roadmap for MedTech start-ups and investors